APO Research
Talk to an analyst

APO RESEARCH · REPORT

Brand Drugs

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Brand Drugs Market Analysis and Forecast 2026-2032

22 December 2025204 pages

Choose your research edition.

Industry ResearchBrand Drugs Industry Research Report 2026139 pages · $2,950 USDIndustry Growth & TrendsGlobal Brand Drugs Industry Growth and Trends Forecast to 2032121 pages · $3,450 USDMarket StructureGlobal Brand Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Brand Drugs Market Outlook and Growth Opportunities 2026202 pages · $4,250 USDMarket Analysis & ForecastGlobal Brand Drugs Market Analysis and Forecast 2026-2032204 pages · $4,950 USD

Market perspective

The global Brand Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Brand Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Brand Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Brand Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Brand Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Brand Drugs include Takeda, Takeda, Teva, Sanofi, Johnson & Johnson, Novartis, Novo Nordisk, Roche and Eli Lilly, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Brand Drugs, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Brand Drugs, also provides the revenue of main regions and countries. Of the upcoming market potential for Brand Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Brand Drugs revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Brand Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Brand Drugs revenue, projected growth trends, production technology, application and end-user industry.

Brand Drugs Segment by Company

Takeda

Takeda

Teva

Sanofi

Johnson & Johnson

Novartis

Novo Nordisk

Roche

Eli Lilly

Pfizer

GlaxoSmithKline (GSK)

Bayer

Amgen

AbbVie

AbbVie

AstraZeneca

Merck & Co. (MSD)

Gilead Sciences

Bristol-Myers Squibb

Boehringer Ingelheim

Brand Drugs Segment by Type

Biopharmaceutical

Chemistry Medicine

Brand Drugs Segment by Application

Hospital

Clinic

Other

Brand Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Brand Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Brand Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Brand Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Brand Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Brand Drugs company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Brand Drugs revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Brand Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Biopharmaceutical Major Player Table 3. Chemistry Medicine Major Player Table 4. Global Brand Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Hospital Major Player Table 6. Clinic Major Player Table 7. Other Major Player Table 8. Brand Drugs Industry Trends Table 9. Brand Drugs Industry Drivers Table 10. Brand Drugs Industry Opportunities and Challenges Table 11. Brand Drugs Industry Restraints Table 12. Global Brand Drugs Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 13. Global Brand Drugs Market Size by Region (2021-2026) & (US$ Million) Table 14. Global Brand Drugs Market Share by Region (2021-2026) Table 15. Global Brand Drugs Market Size by Region (2027-2032) & (US$ Million) Table 16. Global Brand Drugs Market Share by Region (2027-2032) Table 17. Global Brand Drugs Revenue by Players (US$ Million) & (2021-2026) Table 18. Global Brand Drugs Revenue Market Share by Players (2021-2026) Table 19. Global Brand Drugs Key Players Ranking, 2024 VS 2025 VS 2026 Table 20. Global Brand Drugs Key Players Headquarters & Area Served Table 21. Global Brand Drugs Players, Product Type & Application Table 22. Global Brand Drugs Players Establishment Date Table 23. Global Players Market Concentration Ratio (CR5 and HHI) Table 24. Global Brand Drugs by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 25. Global Brand Drugs Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Brand Drugs Revenue by Type (2021-2026) & (US$ Million) Table 27. Global Brand Drugs Revenue by Type (2027-2032) & (US$ Million) Table 28. Global Brand Drugs Revenue Market Share by Type (2021-2026) Table 29. Global Brand Drugs Revenue Market Share by Type (2027-2032) Table 30. Global Brand Drugs Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Brand Drugs Revenue by Application (2021-2026) & (US$ Million) Table 32. Global Brand Drugs Revenue by Application (2027-2032) & (US$ Million) Table 33. Global Brand Drugs Revenue Market Share by Application (2021-2026) Table 34. Global Brand Drugs Revenue Market Share by Application (2027-2032) Table 35. Takeda Company Information Table 36. Takeda Business Overview Table 37. Takeda Brand Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Takeda Brand Drugs Product Portfolio Table 39. Takeda Recent Development Table 40. Takeda Company Information Table 41. Takeda Business Overview Table 42. Takeda Brand Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Takeda Brand Drugs Product Portfolio Table 44. Takeda Recent Development Table 45. Teva Company Information Table 46. Teva Business Overview Table 47. Teva Brand Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Teva Brand Drugs Product Portfolio Table 49. Teva Recent Development Table 50. Sanofi Company Information Table 51. Sanofi Business Overview Table 52. Sanofi Brand Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Sanofi Brand Drugs Product Portfolio Table 54. Sanofi Recent Development Table 55. Johnson & Johnson Company Information Table 56. Johnson & Johnson Business Overview Table 57. Johnson & Johnson Brand Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Johnson & Johnson Brand Drugs Product Portfolio Table 59. Johnson & Johnson Recent Development Table 60. Novartis Company Information Table 61. Novartis Business Overview Table 62. Novartis Brand Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. Novartis Brand Drugs Product Portfolio Table 64. Novartis Recent Development Table 65. Novo Nordisk Company Information Table 66. Novo Nordisk Business Overview Table 67. Novo Nordisk Brand Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. Novo Nordisk Brand Drugs Product Portfolio Table 69. Novo Nordisk Recent Development Table 70. Roche Company Information Table 71. Roche Business Overview Table 72. Roche Brand Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. Roche Brand Drugs Product Portfolio Table 74. Roche Recent Development Table 75. Eli Lilly Company Information Table 76. Eli Lilly Business Overview Table 77. Eli Lilly Brand Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. Eli Lilly Brand Drugs Product Portfolio Table 79. Eli Lilly Recent Development Table 80. Pfizer Company Information Table 81. Pfizer Business Overview Table 82. Pfizer Brand Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 83. Pfizer Brand Drugs Product Portfolio Table 84. Pfizer Recent Development Table 85. GlaxoSmithKline (GSK) Company Information Table 86. GlaxoSmithKline (GSK) Business Overview Table 87. GlaxoSmithKline (GSK) Brand Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 88. GlaxoSmithKline (GSK) Brand Drugs Product Portfolio Table 89. GlaxoSmithKline (GSK) Recent Development Table 90. Bayer Company Information Table 91. Bayer Business Overview Table 92. Bayer Brand Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 93. Bayer Brand Drugs Product Portfolio Table 94. Bayer Recent Development Table 95. Amgen Company Information Table 96. Amgen Business Overview Table 97. Amgen Brand Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 98. Amgen Brand Drugs Product Portfolio Table 99. Amgen Recent Development Table 100. AbbVie Company Information Table 101. AbbVie Business Overview Table 102. AbbVie Brand Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 103. AbbVie Brand Drugs Product Portfolio Table 104. AbbVie Recent Development Table 105. AbbVie Company Information Table 106. AbbVie Business Overview Table 107. AbbVie Brand Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 108. AbbVie Brand Drugs Product Portfolio Table 109. AbbVie Recent Development Table 110. AstraZeneca Company Information Table 111. AstraZeneca Business Overview Table 112. AstraZeneca Brand Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 113. AstraZeneca Brand Drugs Product Portfolio Table 114. AstraZeneca Recent Development Table 115. Merck & Co. (MSD) Company Information Table 116. Merck & Co. (MSD) Business Overview Table 117. Merck & Co. (MSD) Brand Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 118. Merck & Co. (MSD) Brand Drugs Product Portfolio Table 119. Merck & Co. (MSD) Recent Development Table 120. Gilead Sciences Company Information Table 121. Gilead Sciences Business Overview Table 122. Gilead Sciences Brand Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 123. Gilead Sciences Brand Drugs Product Portfolio Table 124. Gilead Sciences Recent Development Table 125. Bristol-Myers Squibb Company Information Table 126. Bristol-Myers Squibb Business Overview Table 127. Bristol-Myers Squibb Brand Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 128. Bristol-Myers Squibb Brand Drugs Product Portfolio Table 129. Bristol-Myers Squibb Recent Development Table 130. Boehringer Ingelheim Company Information Table 131. Boehringer Ingelheim Business Overview Table 132. Boehringer Ingelheim Brand Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 133. Boehringer Ingelheim Brand Drugs Product Portfolio Table 134. Boehringer Ingelheim Recent Development Table 135. North America Brand Drugs Revenue by Type (2021-2026) & (US$ Million) Table 136. North America Brand Drugs Revenue by Type (2027-2032) & (US$ Million) Table 137. North America Brand Drugs Revenue by Application (2021-2026) & (US$ Million) Table 138. North America Brand Drugs Revenue by Application (2027-2032) & (US$ Million) Table 139. North America Brand Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 140. North America Brand Drugs Revenue by Country (2021-2026) & (US$ Million) Table 141. North America Brand Drugs Revenue by Country (US$ Million) & (2027-2032) Table 142. Europe Brand Drugs Revenue by Type (2021-2026) & (US$ Million) Table 143. Europe Brand Drugs Revenue by Type (2027-2032) & (US$ Million) Table 144. Europe Brand Drugs Revenue by Application (2021-2026) & (US$ Million) Table 145. Europe Brand Drugs Revenue by Application (2027-2032) & (US$ Million) Table 146. Europe Brand Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 147. Europe Brand Drugs Revenue by Country (2021-2026) & (US$ Million) Table 148. Europe Brand Drugs Revenue by Country (US$ Million) & (2027-2032) Table 149. China Brand Drugs Revenue by Type (2021-2026) & (US$ Million) Table 150. China Brand Drugs Revenue by Type (2027-2032) & (US$ Million) Table 151. China Brand Drugs Revenue by Application (2021-2026) & (US$ Million) Table 152. China Brand Drugs Revenue by Application (2027-2032) & (US$ Million) Table 153. Asia Brand Drugs Revenue by Type (2021-2026) & (US$ Million) Table 154. Asia Brand Drugs Revenue by Type (2027-2032) & (US$ Million) Table 155. Asia Brand Drugs Revenue by Application (2021-2026) & (US$ Million) Table 156. Asia Brand Drugs Revenue by Application (2027-2032) & (US$ Million) Table 157. Asia Brand Drugs Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 158. Asia Brand Drugs Revenue by Region (US$ Million) & (2021-2026) Table 159. Asia Brand Drugs Revenue by Region (US$ Million) & (2027-2032) Table 160. SAMEA Brand Drugs Revenue by Type (2021-2026) & (US$ Million) Table 161. SAMEA Brand Drugs Revenue by Type (2027-2032) & (US$ Million) Table 162. SAMEA Brand Drugs Revenue by Application (2021-2026) & (US$ Million) Table 163. SAMEA Brand Drugs Revenue by Application (2027-2032) & (US$ Million) Table 164. SAMEA Brand Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 165. SAMEA Brand Drugs Revenue by Country (2021-2026) & (US$ Million) Table 166. SAMEA Brand Drugs Revenue by Country (US$ Million) & (2027-2032) Table 167. Research Programs/Design for This Report Table 168. Authors List of This Report Table 169. Secondary Sources Table 170. Primary Sources List of Figures Figure 1. Brand Drugs Image Figure 2. Global Brand Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Brand Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 4. Biopharmaceutical Image Figure 5. Chemistry Medicine Image Figure 6. Global Brand Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Brand Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 8. Hospital Image Figure 9. Clinic Image Figure 10. Other Image Figure 11. Global Brand Drugs Market Size (US$ Million) & (2021-2032) Figure 12. Global Brand Drugs Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Brand Drugs Market Share by Region: 2021 VS 2025 VS 2032 Figure 14. Global Brand Drugs Players Revenue Share Top 10 and Top 5 in 2025 Figure 15. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 16. Global Brand Drugs Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Brand Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Brand Drugs Revenue Market Share by Type (2021-2032) Figure 19. Global Brand Drugs Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Brand Drugs Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 21. Global Brand Drugs Revenue Market Share by Application (2021-2032) Figure 22. North America Brand Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 23. North America Brand Drugs Revenue Share by Type (2021-2032) Figure 24. North America Brand Drugs Revenue Share by Application (2021-2032) Figure 25. North America Brand Drugs Revenue Share by Country (2021-2032) Figure 26. United States Brand Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Canada Brand Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Mexico Brand Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Europe Brand Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 30. Europe Brand Drugs Revenue Share by Type (2021-2032) Figure 31. Europe Brand Drugs Revenue Share by Application (2021-2032) Figure 32. Europe Brand Drugs Revenue Share by Country (2021-2032) Figure 33. Germany Brand Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. France Brand Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. U.K. Brand Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Italy Brand Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Spain Brand Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Russia Brand Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Netherlands Brand Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Nordic Countries Brand Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. China Brand Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 42. China Brand Drugs Revenue Share by Type (2021-2032) Figure 43. China Brand Drugs Revenue Share by Application (2021-2032) Figure 44. Asia Brand Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. Asia Brand Drugs Revenue Share by Type (2021-2032) Figure 46. Asia Brand Drugs Revenue Share by Application (2021-2032) Figure 47. Asia Brand Drugs Revenue Share by Region (2021-2032) Figure 48. Japan Brand Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. South Korea Brand Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. India Brand Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Australia Brand Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Taiwan Brand Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Southeast Asia Brand Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. SAMEA Brand Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 55. SAMEA Brand Drugs Revenue Share by Type (2021-2032) Figure 56. SAMEA Brand Drugs Revenue Share by Application (2021-2032) Figure 57. SAMEA Brand Drugs Revenue Share by Country (2021-2032) Figure 58. Brazil Brand Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Argentina Brand Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Chile Brand Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Colombia Brand Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Peru Brand Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Saudi Arabia Brand Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Israel Brand Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. UAE Brand Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Turkey Brand Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Iran Brand Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Egypt Brand Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Biopharmaceutical
  • Chemistry Medicine
Applications
  • Hospital
  • Clinic
  • Other
Companies covered
  • Takeda
  • Takeda
  • Teva
  • Sanofi
  • Johnson & Johnson
  • Novartis
  • Novo Nordisk
  • Roche
  • Eli Lilly
  • Pfizer
  • GlaxoSmithKline (GSK)
  • Bayer
  • Amgen
  • AbbVie
  • AbbVie
  • AstraZeneca
  • Merck & Co. (MSD)
  • Gilead Sciences
  • Bristol-Myers Squibb
  • Boehringer Ingelheim

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Brand Drugs Market by Type
  3. 1.2.1 Global Brand Drugs Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Biopharmaceutical
  5. 1.2.3 Chemistry Medicine
  6. 1.3 Brand Drugs Market by Application
  7. 1.3.1 Global Brand Drugs Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Hospital
  9. 1.3.3 Clinic
  10. 1.3.4 Other
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Brand Drugs Market Dynamics
  1. 2.1 Brand Drugs Industry Trends
  2. 2.2 Brand Drugs Industry Drivers
  3. 2.3 Brand Drugs Industry Opportunities and Challenges
  4. 2.4 Brand Drugs Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Brand Drugs Market Perspective (2021-2032)
  2. 3.2 Global Brand Drugs Growth Trends by Region
  3. 3.2.1 Global Brand Drugs Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Brand Drugs Market Size by Region (2021-2026)
  5. 3.2.3 Global Brand Drugs Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Brand Drugs Revenue by Players
  2. 4.1.1 Global Brand Drugs Revenue by Players (2021-2026)
  3. 4.1.2 Global Brand Drugs Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Brand Drugs Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Brand Drugs Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Brand Drugs Key Players Headquarters & Area Served
  7. 4.4 Global Brand Drugs Players, Product Type & Application
  8. 4.5 Global Brand Drugs Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Brand Drugs Market CR5 and HHI
  11. 4.6.3 2025 Brand Drugs Tier 1, Tier 2, and Tier 3
5 Brand Drugs Market Size by Type
  1. 5.1 Global Brand Drugs Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Brand Drugs Revenue by Type (2021-2032)
  3. 5.3 Global Brand Drugs Revenue Market Share by Type (2021-2032)
6 Brand Drugs Market Size by Application
  1. 6.1 Global Brand Drugs Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Brand Drugs Revenue by Application (2021-2032)
  3. 6.3 Global Brand Drugs Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Takeda
  2. 7.1.1 Takeda Company Information
  3. 7.1.2 Takeda Business Overview
  4. 7.1.3 Takeda Brand Drugs Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Takeda Brand Drugs Product Portfolio
  6. 7.1.5 Takeda Recent Developments
  7. 7.2 Takeda
  8. 7.2.1 Takeda Company Information
  9. 7.2.2 Takeda Business Overview
  10. 7.2.3 Takeda Brand Drugs Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Takeda Brand Drugs Product Portfolio
  12. 7.2.5 Takeda Recent Developments
  13. 7.3 Teva
  14. 7.3.1 Teva Company Information
  15. 7.3.2 Teva Business Overview
  16. 7.3.3 Teva Brand Drugs Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Teva Brand Drugs Product Portfolio
  18. 7.3.5 Teva Recent Developments
  19. 7.4 Sanofi
  20. 7.4.1 Sanofi Company Information
  21. 7.4.2 Sanofi Business Overview
  22. 7.4.3 Sanofi Brand Drugs Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Sanofi Brand Drugs Product Portfolio
  24. 7.4.5 Sanofi Recent Developments
  25. 7.5 Johnson & Johnson
  26. 7.5.1 Johnson & Johnson Company Information
  27. 7.5.2 Johnson & Johnson Business Overview
  28. 7.5.3 Johnson & Johnson Brand Drugs Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Johnson & Johnson Brand Drugs Product Portfolio
  30. 7.5.5 Johnson & Johnson Recent Developments
  31. 7.6 Novartis
  32. 7.6.1 Novartis Company Information
  33. 7.6.2 Novartis Business Overview
  34. 7.6.3 Novartis Brand Drugs Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Novartis Brand Drugs Product Portfolio
  36. 7.6.5 Novartis Recent Developments
  37. 7.7 Novo Nordisk
  38. 7.7.1 Novo Nordisk Company Information
  39. 7.7.2 Novo Nordisk Business Overview
  40. 7.7.3 Novo Nordisk Brand Drugs Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Novo Nordisk Brand Drugs Product Portfolio
  42. 7.7.5 Novo Nordisk Recent Developments
  43. 7.8 Roche
  44. 7.8.1 Roche Company Information
  45. 7.8.2 Roche Business Overview
  46. 7.8.3 Roche Brand Drugs Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Roche Brand Drugs Product Portfolio
  48. 7.8.5 Roche Recent Developments
  49. 7.9 Eli Lilly
  50. 7.9.1 Eli Lilly Company Information
  51. 7.9.2 Eli Lilly Business Overview
  52. 7.9.3 Eli Lilly Brand Drugs Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Eli Lilly Brand Drugs Product Portfolio
  54. 7.9.5 Eli Lilly Recent Developments
  55. 7.10 Pfizer
  56. 7.10.1 Pfizer Company Information
  57. 7.10.2 Pfizer Business Overview
  58. 7.10.3 Pfizer Brand Drugs Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Pfizer Brand Drugs Product Portfolio
  60. 7.10.5 Pfizer Recent Developments
  61. 7.11 GlaxoSmithKline (GSK)
  62. 7.11.1 GlaxoSmithKline (GSK) Company Information
  63. 7.11.2 GlaxoSmithKline (GSK) Business Overview
  64. 7.11.3 GlaxoSmithKline (GSK) Brand Drugs Revenue and Gross Margin (2021-2026)
  65. 7.11.4 GlaxoSmithKline (GSK) Brand Drugs Product Portfolio
  66. 7.11.5 GlaxoSmithKline (GSK) Recent Developments
  67. 7.12 Bayer
  68. 7.12.1 Bayer Company Information
  69. 7.12.2 Bayer Business Overview
  70. 7.12.3 Bayer Brand Drugs Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Bayer Brand Drugs Product Portfolio
  72. 7.12.5 Bayer Recent Developments
  73. 7.13 Amgen
  74. 7.13.1 Amgen Company Information
  75. 7.13.2 Amgen Business Overview
  76. 7.13.3 Amgen Brand Drugs Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Amgen Brand Drugs Product Portfolio
  78. 7.13.5 Amgen Recent Developments
  79. 7.14 AbbVie
  80. 7.14.1 AbbVie Company Information
  81. 7.14.2 AbbVie Business Overview
  82. 7.14.3 AbbVie Brand Drugs Revenue and Gross Margin (2021-2026)
  83. 7.14.4 AbbVie Brand Drugs Product Portfolio
  84. 7.14.5 AbbVie Recent Developments
  85. 7.15 AbbVie
  86. 7.15.1 AbbVie Company Information
  87. 7.15.2 AbbVie Business Overview
  88. 7.15.3 AbbVie Brand Drugs Revenue and Gross Margin (2021-2026)
  89. 7.15.4 AbbVie Brand Drugs Product Portfolio
  90. 7.15.5 AbbVie Recent Developments
  91. 7.16 AstraZeneca
  92. 7.16.1 AstraZeneca Company Information
  93. 7.16.2 AstraZeneca Business Overview
  94. 7.16.3 AstraZeneca Brand Drugs Revenue and Gross Margin (2021-2026)
  95. 7.16.4 AstraZeneca Brand Drugs Product Portfolio
  96. 7.16.5 AstraZeneca Recent Developments
  97. 7.17 Merck & Co. (MSD)
  98. 7.17.1 Merck & Co. (MSD) Company Information
  99. 7.17.2 Merck & Co. (MSD) Business Overview
  100. 7.17.3 Merck & Co. (MSD) Brand Drugs Revenue and Gross Margin (2021-2026)
  101. 7.17.4 Merck & Co. (MSD) Brand Drugs Product Portfolio
  102. 7.17.5 Merck & Co. (MSD) Recent Developments
  103. 7.18 Gilead Sciences
  104. 7.18.1 Gilead Sciences Company Information
  105. 7.18.2 Gilead Sciences Business Overview
  106. 7.18.3 Gilead Sciences Brand Drugs Revenue and Gross Margin (2021-2026)
  107. 7.18.4 Gilead Sciences Brand Drugs Product Portfolio
  108. 7.18.5 Gilead Sciences Recent Developments
  109. 7.19 Bristol-Myers Squibb
  110. 7.19.1 Bristol-Myers Squibb Company Information
  111. 7.19.2 Bristol-Myers Squibb Business Overview
  112. 7.19.3 Bristol-Myers Squibb Brand Drugs Revenue and Gross Margin (2021-2026)
  113. 7.19.4 Bristol-Myers Squibb Brand Drugs Product Portfolio
  114. 7.19.5 Bristol-Myers Squibb Recent Developments
  115. 7.20 Boehringer Ingelheim
  116. 7.20.1 Boehringer Ingelheim Company Information
  117. 7.20.2 Boehringer Ingelheim Business Overview
  118. 7.20.3 Boehringer Ingelheim Brand Drugs Revenue and Gross Margin (2021-2026)
  119. 7.20.4 Boehringer Ingelheim Brand Drugs Product Portfolio
  120. 7.20.5 Boehringer Ingelheim Recent Developments
8 North America
  1. 8.1 North America Brand Drugs Revenue (2021-2032)
  2. 8.2 North America Brand Drugs Revenue by Type (2021-2032)
  3. 8.2.1 North America Brand Drugs Revenue by Type (2021-2026)
  4. 8.2.2 North America Brand Drugs Revenue by Type (2027-2032)
  5. 8.3 North America Brand Drugs Revenue Share by Type (2021-2032)
  6. 8.4 North America Brand Drugs Revenue by Application (2021-2032)
  7. 8.4.1 North America Brand Drugs Revenue by Application (2021-2026)
  8. 8.4.2 North America Brand Drugs Revenue by Application (2027-2032)
  9. 8.5 North America Brand Drugs Revenue Share by Application (2021-2032)
  10. 8.6 North America Brand Drugs Revenue by Country
  11. 8.6.1 North America Brand Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Brand Drugs Revenue by Country (2021-2026)
  13. 8.6.3 North America Brand Drugs Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Brand Drugs Revenue (2021-2032)
  2. 9.2 Europe Brand Drugs Revenue by Type (2021-2032)
  3. 9.2.1 Europe Brand Drugs Revenue by Type (2021-2026)
  4. 9.2.2 Europe Brand Drugs Revenue by Type (2027-2032)
  5. 9.3 Europe Brand Drugs Revenue Share by Type (2021-2032)
  6. 9.4 Europe Brand Drugs Revenue by Application (2021-2032)
  7. 9.4.1 Europe Brand Drugs Revenue by Application (2021-2026)
  8. 9.4.2 Europe Brand Drugs Revenue by Application (2027-2032)
  9. 9.5 Europe Brand Drugs Revenue Share by Application (2021-2032)
  10. 9.6 Europe Brand Drugs Revenue by Country
  11. 9.6.1 Europe Brand Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Brand Drugs Revenue by Country (2021-2026)
  13. 9.6.3 Europe Brand Drugs Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Brand Drugs Revenue (2021-2032)
  2. 10.2 China Brand Drugs Revenue by Type (2021-2032)
  3. 10.2.1 China Brand Drugs Revenue by Type (2021-2026)
  4. 10.2.2 China Brand Drugs Revenue by Type (2027-2032)
  5. 10.3 China Brand Drugs Revenue Share by Type (2021-2032)
  6. 10.4 China Brand Drugs Revenue by Application (2021-2032)
  7. 10.4.1 China Brand Drugs Revenue by Application (2021-2026)
  8. 10.4.2 China Brand Drugs Revenue by Application (2027-2032)
  9. 10.5 China Brand Drugs Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Brand Drugs Revenue (2021-2032)
  2. 11.2 Asia Brand Drugs Revenue by Type (2021-2032)
  3. 11.2.1 Asia Brand Drugs Revenue by Type (2021-2026)
  4. 11.2.2 Asia Brand Drugs Revenue by Type (2027-2032)
  5. 11.3 Asia Brand Drugs Revenue Share by Type (2021-2032)
  6. 11.4 Asia Brand Drugs Revenue by Application (2021-2032)
  7. 11.4.1 Asia Brand Drugs Revenue by Application (2021-2026)
  8. 11.4.2 Asia Brand Drugs Revenue by Application (2027-2032)
  9. 11.5 Asia Brand Drugs Revenue Share by Application (2021-2032)
  10. 11.6 Asia Brand Drugs Revenue by Country
  11. 11.6.1 Asia Brand Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Brand Drugs Revenue by Country (2021-2026)
  13. 11.6.3 Asia Brand Drugs Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Brand Drugs Revenue (2021-2032)
  2. 12.2 SAMEA Brand Drugs Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Brand Drugs Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Brand Drugs Revenue by Type (2027-2032)
  5. 12.3 SAMEA Brand Drugs Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Brand Drugs Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Brand Drugs Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Brand Drugs Revenue by Application (2027-2032)
  9. 12.5 SAMEA Brand Drugs Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Brand Drugs Revenue by Country
  11. 12.6.1 SAMEA Brand Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Brand Drugs Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Brand Drugs Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst